Exane BNP Paribas initiated coverage of Genmab with an Underperform rating and DKK 2,000 price target. The company’s “cash cow” Darzalex is facing risk of an “abrupt end” at the turn of the decade and its pipeline is under “significant pressure to deliver,” the analyst tells investors in a research note. The firm sees no easy answer for Genmab.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GMAB:
- Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023
- Genmab reports Q3 worldwide net sales of DARZALEX $2.499B
- Genmab price target raised to $46 from $44 at BTIG
- Genmab downgraded to Hold from Buy at Nordea
- Grant of Restricted Stock Units and Warrants to Employees in Genmab